Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
$70.82
$0.33(1.68%)
At close: 4:00 PM EST
$70.82
$0.33(1.68%)
Day’s Range― - ―
52-Week Range$9.57 - $71.50
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.71M
Market Cap
$9.35B
Enterprise Value$4.53B
Total Cash (Recent Filing)$900.37M
Total Debt (Recent Filing)$713.29M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Feb 10, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding135,809,560
10 Day Avg. Volume3,767,372
30 Day Avg. Volume2,714,745
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit7.86
Enterprise Value/Ebitda-86.32
Forecast
1Y Price Target
$67.50Price Target Upside-4.69% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.18
Revenue Forecast (FY)$391.91M
Bulls Say, Bears Say
Bulls Say
FDA Approval And LaunchThe FDA approved REDEMPLO (plozasiran) as the first siRNA therapy for familial chylomicronemia syndrome (FCS), marking a transformative entry into the APOC3 landscape with a best-in-class profile.
Financial Stability And GrowthArrowhead ended the fiscal year with $782 million in cash, supporting operations into fiscal 2028.
Obesity Treatment AdvancementsARO-INHBE and ARO-ALK7 represent promising novel mechanisms to treat obesity and metabolic diseases, with genetically validated targets associated with reduced abdominal fat and lower risk of metabolic conditions.
Bears Say
Sales GuidanceArrowhead does not plan to provide sales guidance for 2026 as the pricing combined with the small patient population make it unlikely to have a substantial impact.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $71.50 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $9.35B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Feb 10, 2026 which is in 58 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Nov 25, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.112 by $0.002.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Overvalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is 0.12.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 135,809,560 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.112. Following the earnings report the stock price went up 23.338%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
Arrowhead Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.50 (-4.69% Downside)
$67.50 (-4.69% Downside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 15.5%
Last 30 Days ▲ 15.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.91%
12-Months-Change
Fundamentals
Return on Equity
-0.50%
Trailing 12-Months
Asset Growth
27.25%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of serious diseases by leveraging its proprietary RNA interference (RNAi) technology. The company operates primarily in the biotechnology sector, with a focus on developing therapies for liver diseases, cancer, and other serious health conditions. Arrowhead's core product candidates include ARO-AAT for the treatment of alpha-1 antitrypsin deficiency and ARO-HBV for hepatitis B, among others, which are designed to silence specific genes implicated in disease pathology.
ARWR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant highlights including the FDA approval of Rodemplo, robust financial performance, and substantial milestone payments indicating a successful transition to a commercial stage. However, there are some challenges in program timelines and regulatory claims that need to be addressed.View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
$67.50
▼(-4.69% Downside)
Technical Analysis
Ownership Overview
4.10% Insiders
17.70% Mutual Funds
6.01% Other Institutional Investors
45.61% Public Companies and
Individual Investors